Current Trends in Targeted Therapies for Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is one of the most frequently occurring tumors in the central nervous system and the most malignant tumor among gliomas. Despite aggressive treatment including surgery, adjuvant TMZ-based chemotherapy, and radiotherapy, GBM still has a dismal prognosis: the median survi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Neurology Research International |
| Online Access: | http://dx.doi.org/10.1155/2012/878425 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555855511289856 |
|---|---|
| author | Fumiharu Ohka Atsushi Natsume Toshihiko Wakabayashi |
| author_facet | Fumiharu Ohka Atsushi Natsume Toshihiko Wakabayashi |
| author_sort | Fumiharu Ohka |
| collection | DOAJ |
| description | Glioblastoma multiforme (GBM) is one of the most frequently occurring tumors in the central nervous system and the most malignant tumor among gliomas. Despite aggressive treatment including surgery, adjuvant TMZ-based chemotherapy, and radiotherapy, GBM still has a dismal prognosis: the median survival is 14.6 months from diagnosis. To date, many studies report several determinants of resistance to this aggressive therapy: (1) O6-methylguanine-DNA methyltransferase (MGMT), (2) the complexity of several altered signaling pathways in GBM, (3) the existence of glioma stem-like cells (GSCs), and (4) the blood-brain barrier.
Many studies aim to overcome these determinants of resistance to conventional therapy by using various approaches to improve the dismal prognosis of GBM such as modifying TMZ administration and combining TMZ with other agents, developing novel molecular-targeting agents, and novel strategies targeting GSCs. In this paper, we review up-to-date clinical trials of GBM treatments in order to overcome these 4 hurdles and to aim at more therapeutical effect than conventional therapies that are ongoing or are about to launch in clinical settings and discuss future perspectives. |
| format | Article |
| id | doaj-art-44a7c69c1006465ca5863ec0f48fe018 |
| institution | Kabale University |
| issn | 2090-1852 2090-1860 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neurology Research International |
| spelling | doaj-art-44a7c69c1006465ca5863ec0f48fe0182025-02-03T05:46:54ZengWileyNeurology Research International2090-18522090-18602012-01-01201210.1155/2012/878425878425Current Trends in Targeted Therapies for Glioblastoma MultiformeFumiharu Ohka0Atsushi Natsume1Toshihiko Wakabayashi2Department of Neurosurgery, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, JapanDepartment of Neurosurgery, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, JapanDepartment of Neurosurgery, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, JapanGlioblastoma multiforme (GBM) is one of the most frequently occurring tumors in the central nervous system and the most malignant tumor among gliomas. Despite aggressive treatment including surgery, adjuvant TMZ-based chemotherapy, and radiotherapy, GBM still has a dismal prognosis: the median survival is 14.6 months from diagnosis. To date, many studies report several determinants of resistance to this aggressive therapy: (1) O6-methylguanine-DNA methyltransferase (MGMT), (2) the complexity of several altered signaling pathways in GBM, (3) the existence of glioma stem-like cells (GSCs), and (4) the blood-brain barrier. Many studies aim to overcome these determinants of resistance to conventional therapy by using various approaches to improve the dismal prognosis of GBM such as modifying TMZ administration and combining TMZ with other agents, developing novel molecular-targeting agents, and novel strategies targeting GSCs. In this paper, we review up-to-date clinical trials of GBM treatments in order to overcome these 4 hurdles and to aim at more therapeutical effect than conventional therapies that are ongoing or are about to launch in clinical settings and discuss future perspectives.http://dx.doi.org/10.1155/2012/878425 |
| spellingShingle | Fumiharu Ohka Atsushi Natsume Toshihiko Wakabayashi Current Trends in Targeted Therapies for Glioblastoma Multiforme Neurology Research International |
| title | Current Trends in Targeted Therapies for Glioblastoma Multiforme |
| title_full | Current Trends in Targeted Therapies for Glioblastoma Multiforme |
| title_fullStr | Current Trends in Targeted Therapies for Glioblastoma Multiforme |
| title_full_unstemmed | Current Trends in Targeted Therapies for Glioblastoma Multiforme |
| title_short | Current Trends in Targeted Therapies for Glioblastoma Multiforme |
| title_sort | current trends in targeted therapies for glioblastoma multiforme |
| url | http://dx.doi.org/10.1155/2012/878425 |
| work_keys_str_mv | AT fumiharuohka currenttrendsintargetedtherapiesforglioblastomamultiforme AT atsushinatsume currenttrendsintargetedtherapiesforglioblastomamultiforme AT toshihikowakabayashi currenttrendsintargetedtherapiesforglioblastomamultiforme |